Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Guidelines for Nursing Documentation II01:26

Guidelines for Nursing Documentation II

1.6K
Effective documentation is an integral part of nursing practice. Here are some essential guidelines to follow when documenting patient care:
Timely documentation is crucial to ensure continuity of care for patients. Any delays in recording or reporting medical information can result in medical errors and even adverse patient outcomes. From medication administration to diagnostic test results, every detail must be accurately and promptly documented to provide the best possible care for patients.
1.6K
Legal Guidelines for Documentation01:06

Legal Guidelines for Documentation

2.1K
The legal guidelines for nursing documentation are essential for ensuring accurate, professional, and ethical recording of patient care. The guidelines are discussed here:
2.1K
Guidelines for Sketching a Curve01:23

Guidelines for Sketching a Curve

110
Curve sketching is a systematic method for understanding the overall behavior of a function by analyzing its key mathematical features. A function defines a curve on the coordinate plane, where the horizontal axis represents the input variable and the vertical axis represents the output. The process begins by determining the domain, which specifies the set of input values for which the function is defined and establishes the horizontal extent of the graph.Intercepts with the horizontal and...
110
Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

3.7K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
3.7K
Guidelines for Nursing Documentation I01:30

Guidelines for Nursing Documentation I

1.8K
Quality documentation and reporting share essential characteristics that ensure they are practical and valuable resources for those who use them. These characteristics are:
Factual:  
The following points emphasize the significance of upholding accurate and unbiased documentation in healthcare.
1.8K
Guidelines For Measuring Vital Signs01:19

Guidelines For Measuring Vital Signs

2.8K
Following these guidelines can help nurses accurately measure vital signs, assess changes in patient conditions, and provide timely treatment when necessary. Adhering closely to the guidelines ensures the accuracy and reliability of the results.
Before taking a patient's vital signs, a nurse would consider and assess the patient's comfort level and ensure appropriate equipment is available.
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Rethinking Cardiovascular Events, End Points, and Surveillance in Oncology Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Blood cancer journal·2026
Same author

A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Blood cancer discovery·2026
Same author

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Blood advances·2026
Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: Jan 23, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.6K

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

Andrew D Zelenetz1, Leo I Gordon2, Jeremy S Abramson3

  • 1Memorial Sloan Kettering Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|June 15, 2019
PubMed
Summary
This summary is machine-generated.

New treatments like CAR T-cell therapy offer hope for patients with transformed follicular lymphoma (TFL) and relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These advancements update guidelines for B-cell lymphomas.

More Related Videos

Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
17:59

Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice

Published on: April 3, 2011

12.7K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

784

Related Experiment Videos

Last Updated: Jan 23, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.6K
Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
17:59

Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice

Published on: April 3, 2011

12.7K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

784

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Diffuse large B-cell lymphomas (DLBCL) and follicular lymphoma (FL) are common adult B-cell non-Hodgkin's lymphomas.
  • Histologic transformation of FL to DLBCL (TFL) affects about 15% of patients and typically has a poor prognosis.
  • Phosphatidylinositol 3-kinase (PI3K) inhibitors show promise for relapsed/refractory FL.

Purpose of the Study:

  • To highlight updates in the NCCN Guidelines for B-Cell Lymphomas.
  • To focus on treatment advancements for transformed FL (TFL) and relapsed/refractory DLBCL and FL.

Main Methods:

  • Review of NCCN Guidelines for B-Cell Lymphomas.
  • Inclusion of data on novel therapeutic approaches.

Main Results:

  • CAR T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) is a new option for relapsed/refractory DLBCL and TFL.
  • PI3K inhibitors are effective in relapsed/refractory FL.

Conclusions:

  • Updated NCCN Guidelines provide new treatment strategies for TFL and relapsed/refractory FL and DLBCL.
  • CAR T-cell therapy represents a significant advancement in managing these challenging B-cell lymphomas.